Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
Retatrutide Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-RETA-001
Version: 1.1
Effective Date: 10 December 2025
Product: Retatrutide Research Peptide (RUO)
1. Product Overview
| Parameter | Specification |
|---|---|
| INN (Proposed) | Retatrutide |
| CAS Status | Provisional internal code only (INN submitted; CAS pending EMA/FDA assignment) |
| Molecular Formula | C₁₉₈H₃₀₆N₅₀O₅₈S₁ (sequence-confirmed) |
| Molecular Weight | ~4381.0 g/mol (monoisotopic) |
| Sequence | H-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH₂ |
| Receptor Profile | Balanced triple agonist: GLP-1R / GIPR / GCGR |
| Form Supplied | Lyophilised solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (gradient elution, C18 column) |
| Endotoxin | <1.0 EU/mg (LAL kinetic assay) |
| Residual Solvents | Meets ICH Q3C Class 3 limits (≤5000 ppm total) |
| RUO Status | For research use only — not for human or veterinary use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
|---|---|---|
| −20°C, desiccated, dark | ≥24 months | Preferred long-term storage. Use airtight secondary container with desiccant (e.g., silica gel). |
| 2–8°C (refrigerated) | ≤6 months | Acceptable for short-term; monitor for clumping or discolouration. |
| Room Temp (≤25°C) | ≤7 days | For transit only. Avoid humidity (>60% RH accelerates degradation). |
📌 Do not store lyophilised peptide in frost-free freezers (temperature cycling causes moisture ingress).
✅ Reconstituted (Solution)
| Solvent | Short-Term (2–8°C) | Long-Term (−80°C) | Notes |
|---|---|---|---|
| 0.1% acetic acid in 0.9% NaCl | ≤72 hours | ≤6 months (aliquoted) | Preferred for GCGR-domain stability |
| Bacteriostatic water (0.9% BA) | ≤48 hours | ≤3 months (aliquoted) | Benzyl alcohol may enhance solubility but monitor for aggregation |
| Sterile PBS (pH 7.4) | ≤24 hours | Not recommended | Risk of rapid fibril formation due to neutral pH |
⚠️ Critical:
– Aliquot before freezing — limit freeze–thaw cycles to ≤3.
– Avoid repeated warming/cooling — GCGR-active peptides show accelerated β-sheet aggregation after cycle 2.
– Use low-binding tubes (e.g., LoBind Eppendorf) to minimise adsorption loss.
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on Retatrutide | Detection Method |
|---|---|---|
| Moisture exposure | Hydrolysis at Asp⁹, Asp¹⁴; succinimide formation | HPLC peak broadening, +18 Da MS shift |
| Oxidation (Met, Trp, Cys¹) | Methionine sulfoxide (+16 Da), Trp oxidation | LC-MS, loss of receptor potency in cAMP assays |
| Aggregation/fibrillation | Visible haze, precipitate, or gelation | Dynamic light scattering (DLS), Thioflavin T assay |
| pH >7.0 | Rapid deamidation (Asn, Gln), backbone cleavage | CE, ion-exchange HPLC |
| Repeated freeze–thaw | Irreversible oligomerisation | SEC-HPLC, reduced bioactivity in cell assays |
🔬 Tip: Run a quick spot-check HPLC before critical assays if material has been stored >3 months.
4. Reconstitution Protocol (Best Practice)
- Equilibrate vial to room temp (15–30 min) before opening to prevent condensation.
- Centrifuge briefly (5 sec) to collect powder.
- Add solvent slowly down vial wall (e.g., 1 mL for 10 mg → 10 mg/mL stock).
- Gently swirl — do not vortex.
- If undissolved: warm to ≤37°C for 2–5 min + low-power sonication (≤30 sec, ice-cooled bath).
- Filter through 0.22 µm PVDF (low-protein-binding) for cell work.
- Aliquot into pre-chilled tubes. Flash-freeze in liquid N₂ or dry ice/ethanol. Store at −80°C.
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
|---|---|---|
| HPLC Purity | ≥95% main peak | After >6 months storage, or pre-critical assay |
| MS Identity | Observed MW ±2 Da of theoretical | Annually, or after suspected contamination |
| Endotoxin | <5 EU/mL in reconstituted solution | Before in vivo or primary cell studies |
| Bioactivity (Optional) | EC₅₀ within 2-fold of CoA (cAMP GLP-1R assay) | For longitudinal studies or publication prep |
6. References & Compliance
- Jastreboff et al. N Engl J Med 2023; 389:296–307. DOI: 10.1056/NEJMoa2301972
- ICH Q1A(R2): Stability Testing of New Drug Substances
- USP <1079>: Good Storage and Distribution Practices
- EMA Guideline on Peptide Impurities (EMA/CHMP/ICH/107464/2022)
- MHRA Guidelines on the Labelling of Unlicensed Medicines (2024) — for reference only (RUO not subject, but aligns with handling ethos)
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties, express or implied, regarding fitness for a particular purpose. Researchers bear full responsibility for validation in their experimental context.
